GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sonoma Pharmaceuticals Inc (NAS:SNOA) » Definitions » Cyclically Adjusted Price-to-FCF

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of Jun. 08, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Sonoma Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sonoma Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Sonoma Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Sonoma Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.101/129.4194*129.4194
=-0.101

Current CPI (Dec. 2023) = 129.4194.

Sonoma Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -9.120 99.695 -11.839
201406 -7.389 100.560 -9.510
201409 -8.772 100.428 -11.304
201412 -5.864 99.070 -7.660
201503 -9.205 99.621 -11.958
201506 -8.110 100.684 -10.425
201509 -5.066 100.392 -6.531
201512 -7.691 99.792 -9.974
201603 -4.317 100.470 -5.561
201606 -5.131 101.688 -6.530
201609 -3.585 101.861 -4.555
201612 -3.409 101.863 -4.331
201703 -6.105 102.862 -7.681
201706 -10.044 103.349 -12.578
201709 -5.436 104.136 -6.756
201712 -4.455 104.011 -5.543
201803 -5.382 105.290 -6.615
201806 -4.455 106.317 -5.423
201809 -4.982 106.507 -6.054
201812 -2.464 105.998 -3.008
201903 -2.105 107.251 -2.540
201906 0.543 108.070 0.650
201909 -0.731 108.329 -0.873
201912 -0.566 108.420 -0.676
202003 -2.092 108.902 -2.486
202006 -1.271 108.767 -1.512
202009 -0.186 109.815 -0.219
202012 0.326 109.897 0.384
202103 -0.711 111.754 -0.823
202106 -0.608 114.631 -0.686
202109 -0.567 115.734 -0.634
202112 -0.106 117.630 -0.117
202203 -0.471 121.301 -0.503
202206 -0.502 125.017 -0.520
202209 -0.598 125.227 -0.618
202212 -0.122 125.222 -0.126
202303 -0.617 127.348 -0.627
202306 -0.047 128.729 -0.047
202309 -0.239 129.860 -0.238
202312 -0.101 129.419 -0.101

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sonoma Pharmaceuticals  (NAS:SNOA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Sonoma Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Sonoma Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, and other countries.
Executives
Chad Norman White officer: Interim CFO 645 MOLLY LANE, SUITE 150, WOODSTOCK GA 30189
Jerome J Dvonch officer: Chief Financial Officer 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Robert Grant Edwards officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Poggetto John Dal officer: Chief Financial Officer 1129 N. MCDOWELL BLVD, PETALUMA CA 94954
Amy Moss Trombly officer: Interim CEO 1314 MAIN STREET, SUITE 102, LOUSIVILLE CO 80027
Frederick J Sandford director, officer: CEO and Interim CFO C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Philippe Weigerstorfer director 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert E Miller officer: Chief Financial Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
James J Schutz director, officer: Chief Operating Officer 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Marc Umscheid officer: Chief Strategy/Mkt Officer OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Robert Allen Northey officer: Exec. VP of Res & Devlpment C/O OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sharon Surrey Barbari director 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Russell Joseph Harrison director OCULUS INNOVATIVE SCIENCES, INC., 1129 NORTH MCDOWELL BLVD., PETALUMA CA 94954
John Mclaughlin director OCULUS INNOVATIVE SCIENCES, INC., 1129 N. MCDOWELL BLVD., PETALUMA CA 94954
Sameer Harish other: Officer of Subsidiary (1) RUTHIGEN, INC., 1129 N. MCDOWELL BLVD, PETALUMA CA 94954

Sonoma Pharmaceuticals (Sonoma Pharmaceuticals) Headlines

From GuruFocus